ClinicalTrials.gg
RecruitingNCT06439823Updated Feb 12, 2025

Controlled Study of Upper and Lower Limb Movements in Patients Patients with Pathologies That Have an Impact on Ambulation or Motor Function

An interventional study of ActiMyo®/Syde® in Neuromuscular Diseases, sponsored by Laurent Servais. Recruiting at 1 site in Belgium. Open to participants aged 2 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-12.

Sponsored by Laurent Servais · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Aug 2022, registered May 2024).
  • Started Aug 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Neuromuscular Diseases with a site in Belgium — 7 open to participants now, 11 under way, 3 of them phase 3. Neuromuscular Diseases · Belgium.

Planned enrollment
8th of 20
200 · median 77
Started
2022
with 2 others
No phase
9 of 23
4 open now
Primary completion
2028-08
later than 7 of 10 live
Registered
19th of 23
by date

Among the 23 studies in Neuromuscular Diseases with a site in Belgium, this one is the 8th largest by planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2022, is one of 9 with no phase, reaches primary completion later than 7 of the 10 other live ones, and was the 19th registered.

Neuromuscular Diseases

361 studies on the registry are indexed under Neuromuscular Diseases; 96 are open to participants now.

Browse Neuromuscular Diseases studies →

Open to participants now

7 of the 23 studies in Neuromuscular Diseases with a site in Belgium are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 69 Neuromuscular Diseases studies recruiting now, 39 (57%) set no upper age limit and 22 (32%) stop at 75 or younger; 35 take children under 18; 16 take healthy volunteers.

This study: 2 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Neuromuscular Diseases with a site in Belgium, or all of them as a file.
02

Study summary

The main aim of the study is to validate the algorithms developed to analyze the signals from the various sensors contained in the magneto-inertial control units and reconstruct upper and lower limb movements under different normal and pathological conditions.

03

Conditions studied

  • Neuromuscular Diseases
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects over 2 years old
  • Male or female
  • Control subjects with no pathologies that have an impact on ambulation or motor function.
  • Signed and, in the case of minors, informed consent signed by the person with parental authority/guardian

Exclusion criteria

Exclusion Criteria:

  • Any other previous or present pathology having an impact on current motor or balance function
  • Recent surgery or trauma to upper or lower limbs, or major surgery or trauma within 6 months of inclusion.
  • For control subjects, athlete of at least national level.
  • Pregnant or breast-feeding women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Patient with neuromuscular disease or control subjects

    Patients and controls will be examined by a neuropediatric or neurologist. they will perform upper and lower limb assessments in a walking laboratory. this study comprises a single session per patient/control subject.

    Device: ActiMyo®/Syde®

Interventions

  • DeviceActiMyo®/Syde®

    Subjects will be equipped with magneto-inertial sensors (ActiMyo®/Syde®) and passive reflective markers belonging to the MoCap® motion capture system.

06

What researchers measure

Primary outcomes

  1. step length and distance

    Validate the algorithms developed to analyze the signals from the various sensors contained in magneto-inertial control units and reconstruct upper and lower limb movements.

    Time frame: 36 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Aug 2028, 72 months after the start.

Of 75 non-industry interventional studies with no phase under Neuromuscular Diseases, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 47. This study's planned 72 months is above that.

Counting every sponsor, half of 84 studies reached it within 25 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2024
First posted
Jun 3, 2024
StartActual
Aug 24, 2022
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Feb 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06439823
Lead sponsor
Laurent Servais
Collaborators
SYSNAV
Responsible party
Laurent Servais (Professor Laurent Servais, Centre Hospitalier Universitaire de Liege) — Sponsor-investigator
First posted
Jun 3, 2024
Start date
Aug 24, 2022
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Feb 12, 2025

Study contacts

Laurie Medard
Contact
laurie.medard@citadelle.be
003243218222

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion